ETHYPHARM is a pharmaceutical company which develops oral modified release formulations through its patented technologies. It focuses on developing, manufacturing and licensing pharmaceutical products based on optimization of delivery through proprietary technologies. Ethypharm is a French company, present on the principal world health markets with manufacturing and R & D sites in Europe, in North America and Asia. It employs 600 people worldwide. The company has a special focus on pain management, cardiovascular, oncology and CNS branded and generic products. Its know-how and dedicated plant for narcotics makes it one of the leading experts in developing and licensing controlled active substances worldwide. Its specificity is to offer its international partners the development of key products, with a total package of services and support, through the pharmaceutical and clinical development to registration and manufacture. Over the years, Ethypharm has developed more than 50 branded and generic products, based on its core proprietary technologies. The Group also develops scientific programs and partnerships, addressing new areas of Drug Delivery through innovative emerging technologies Contacts: Ethypharm Headquarters - 194 Bureaux de la Colline - 92 213 Saint Cloud cedex - France Phone : + 33 (0) 1 41 12 17 20 Contact : Bruno Delie, Jean-Philippe Lacombe, Yann Barrault E-mail : businessdeveloppement@ethypharm.com barrault.yann@ethypharm.com / www.ethypharm.com

Ethypharm is present on all of the world's major healthcare markets with operations in Europe, North America and Asia. Ethypharm has 4 main R&D centers located in France, one in Canada and in Asia. The company has also 5 main manufacturing facilities, and all are Good Manufacturing Practice (GMP) compliant. 3 of them are located in France, the 2 others are in Asia. Ethypharm's sites Châteuneuf-en-Thymerais and Grand Quevilly, France, are FDA approved facilities. Ethypharm has broad range of proprietary technologies including controlled release technology, orally disintegrating dosage forms and enhanced solubilisation systems for poorly solube drugs. In addition, the company has a strong expertise in clinical development and registration. Ethypharm has gained a total of 1,600 approvals for 50 products. Ethypharm is working with more than 100 clients worldwide including many major pharmaceutical companies.

More press releases